Ritonavir Form III: A New Polymorph After 24 Years

Polymorphism occurs widely in pharmaceutical solids, and must be thoroughly studied during product development. Twenty-four years after ritonavir (RTV) Form II materialized, we report a new polymorph, Form III, discovered via melt crystallization. Form III has a unique PXRD pattern, Raman spectrum,...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmaceutical sciences Vol. 112; no. 1; pp. 237 - 242
Main Authors Yao, Xin, Henry, Rodger F., Zhang, Geoff G.Z.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2023
Subjects
Crystal nucleation
Crystal Structure
Crystallization
Hydrogen Bonding
Melt crystallization
Molecular Conformation
Polymorph selection
Polymorphism
Ritonavir
Ritonavir - chemistry
Crystal Structure
Crystal nucleation
Melt crystallization
Polymorph selection
Ritonavir
Polymorphism
Online AccessGet full text

Cover

More Information
Summary:Polymorphism occurs widely in pharmaceutical solids, and must be thoroughly studied during product development. Twenty-four years after ritonavir (RTV) Form II materialized, we report a new polymorph, Form III, discovered via melt crystallization. Form III has a unique PXRD pattern, Raman spectrum, lower melting point and heat of fusion, compared to the known polymorphs, Form I and Form II. It is the least stable form, monotropically, among the three polymorphs. Form III differs from Form I and Form II in molecular conformation and hydrogen bonding motifs in crystal lattice. Nucleation from RTV supercooled liquid is slow, and selected Form III exclusively. The discovery of RTV Form III demonstrates the importance of crystal nucleation studies. Crystallization from supercooled liquids should be incorporated as part of polymorph screening workflow.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-3549
1520-6017
DOI:10.1016/j.xphs.2022.09.026